⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545128 | 0.89 | TDP1 (0.32) | — | |
| SCHEMBL15125228 | 0.89 | — | — | |
| SCHEMBL28268649 | 0.87 | FFAR3 (0.36) | — | |
| SCHEMBL13545190 | 0.87 | FFAR3 (0.36) | — | |
| SCHEMBL16887664 | 0.81 | POLB (0.34) | — | |
| SCHEMBL16887592 | 0.78 | CYP1A2 (0.40) | — | |
| SCHEMBL21242166 | 0.78 | LMNA (0.41) | — | |
| SCHEMBL22504466 | 0.76 | — | — | |
| SCHEMBL28201346 | 0.75 | MMP1 (0.31) | — | |
| SCHEMBL13423765 | 0.74 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776511-B | N-substituted imidazole formate derivative and application thereof | 成都麻沸散医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11434205-B2 | Substituted imidazole carboxylate derivatives and the use thereof | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3747869-A1 | SUBSTITUTED IMIDAZOLE FORMATE DERIVATIVE AND USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20200369621-A1 | SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| WO-2019149228-A1 | SUBSTITUTED IMIDAZOLE FORMATE DERIVATIVE AND USE THEREOF | 成都安诺晨创医药科技有限公司 | 2019-08-08 | — | — | WO | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | disclosed |